USPTO serial 79351089
VALOTX
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- CLARK, ROBERT C
- Law office
- GENERIC WEB UPDATE
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with VALOTX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Marc Phillip Bodner
1175 East 27th StreetBrooklyn, NY 11210UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical and biological reagents for scientific and research use; antioxidants for use in the manufacture of pharmaceuticals; Animal albumen as a raw material for industrial use; collagen for industrial purposes; antioxidants for use in manufacture; biochemical catalysts; chemical preparations for scientific purposes, other than for medical or veterinary use; protein for use in manufacture; preparations of microorganisms, other than for medical and veterinary use; biological preparations for use in industry and science, other than for medical or veterinary purposes; diagnostic preparations, other than for medical or veterinary purposes | ABANDONED | — |
| 005 | Biopharmaceutical and pharmaceutical preparations for treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders; therapeutic agents for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders; veterinary preparations; biological preparations for veterinary purposes for the treatment of tumors, cancers and infectious diseases; cultures of microorganisms for medical and veterinary use; biological preparations for medical purposes for the treatment of tumors, cancers and infectious diseases; drugs for medical purposes for the treatment of tumors, cancers and infectious diseases; diagnostic preparations for medical purposes; enzymes for medical purposes; biochemical medicines for the treatment of tumors, cancers and infectious diseases; vaccines; bioengineering pharmaceutical solutions for use in expanding cells for therapeutic use to patients with blood cancers and other diseases; biopharmaceuticals for the treatment of tumors, cancers and infectious diseases; cells for medical and clinical use, including, blood, stem cells, adult blood cells, immune cells, immunomodulatory cells, umbilical cord cells, umbilical cord blood, and placental tissue; bioengineered cells for use in immunotherapies for cancer and other diseases; diagnostic preparations for medical purposes; Pharmaceutical preparations and vaccines for use in gene therapy and cell therapy; biological preparations for use in medical and clinical gene therapy and cell therapy; pharmaceutical preparations in the nature of cell solutions to enable cell expansion for therapeutic purposes; reagents for medical use for ex vivo cell processing in particular media suitable for the expansion of cells; Stem cells for medical or veterinary use; cells for medical purposes | ABANDONED | — |
| 010 | Medical instruments and apparatus for the administration of gene and cell therapy, immunotherapy and immunomodulation and prophylaxis products; surgical and medical apparatus and instruments for gene and cell therapy, immunotherapy and immunomodulation and prophylaxis; veterinary apparatus and instruments, namely, for use in the treatment of tumors, cancers and infectious diseases; radiological apparatus for medical purposes; diagnostic apparatus for medical purposes, namely for use in the treatment of tumors, cancers and infectious diseases; apparatus for use in medical analysis, namely, for use in the treatment of tumors, cancers and infectious diseases; medical apparatus and instruments for use in the treatment of tumors, cancers and infectious diseases; surgical apparatus and instruments; breast pumps; apparatus, devices and articles for nursing infants, namely, nursing bottles; physiotherapy apparatus, namely, foam positioning pads and rollers for physical therapy use; galvanic therapeutic appliances for medical use; blood testing apparatus; medical devices for ex vivo cell processing | ABANDONED | — |
| 040 | Contract manufacturing of pharmaceuticals, cells and gene therapy reagents, including custom manufacturing services of pharmaceuticals, cells and gene therapy reagents; custom manufacturing services for others in the field of pharmaceuticals, biopharmaceuticals, cellular immunotherapies, health care products and medical products; manufacture of pharmaceuticals and biopharmaceuticals to order and/or specification of others; custom manufacturing of biological tissue, blood, and cells (including stem and progenitor cells, adult cells and immune cells); treatment of materials, namely, pharmaceutical and chemical products and their components used in the manufacture of pharmaceuticals and biopharmaceuticals and cellular immunotherapies | ABANDONED | — |
| 042 | Analysis of biological samples; biopharmaceutical and pharmaceutical development and research and evaluation services in the field of cell based therapeutics and gene therapy for the treatment of disease, injuries and disorders; biotechnology laboratory services; medical and scientific laboratory services; scientific and medical research consultation services and scientific and medical research and development services, including in the field of haematology, immunology, cancer research, developmental biology and life sciences, biotechnology, medical technology, cell culture, tissue engineering, genetic engineering, regenerative medicine, immunotherapy and immunomodulation; clinical research services in the field of in the field of haematology, immunology, cancer research, developmental biology and life sciences, biotechnology, medical technology, cell culture, tissue engineering, genetic engineering, regenerative medicine, immunotherapy and immunomodulation; medical and scientific research, namely, conducting clinical trials for others; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceutical preparations; research and development in the field of computational biology, bioinformatics, and genomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceutical preparations and substances for use in clinical trials; cloud computing; chemical analysis; industrial design; conducting technical project studies; research and development of new products for others; material testing; biological research; scientific laboratory services; scientific research; bacteriological research | ABANDONED | — |
| 044 | Medical services, including regenerative treatment services; medical diagnostic testing, monitoring and reporting services; medical evaluation of immuno-oncological disorders, cancer, diabetes, respiratory, heart, neurological and auto immune disorders; providing health and medical information about medical disorders and their diagnosis, prevention and treatment; cell and gene therapy medical treatment services | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Valo Therapeutics Oy
- Other trademarks owned by Valo Therapeutics Oy
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named VALOTX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 30, 2024 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 8, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 8, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 30, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 7, 2023 | MAB5 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION | — |
| Nov 7, 2023 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Nov 7, 2023 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Nov 7, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 7, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 6, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 2, 2023 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Oct 18, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 18, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 18, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 4, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 2, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 1, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 1, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 25, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 3, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 3, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 11, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 10, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 9, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 23, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 4, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 30, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 29, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |